Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Abdomen-pelvis CT is the nation’s highest-volume CT category
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Subscribe To Our Newsletter & Stay Updated
